^van den Hoogen LL, van Laar JM. Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome. Best Practice & Research. Clinical Rheumatology. February 2020, 34 (1): 101485. PMID 32067925. doi:10.1016/j.berh.2020.101485.
^Narain S, Berman N, Furie R. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis. Current Opinion in Rheumatology. November 2020, 32 (6): 609–616. PMID 33002950. S2CID 222150641. doi:10.1097/BOR.0000000000000754.
^Clinical trial number NCT03574545 for "Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis" at ClinicalTrials.gov
^Clinical trial number NCT03656562 for "Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients" at ClinicalTrials.gov
.
